ArticleEuropean journal of neurology2025
Substantia Nigra Hyperechogenicity Predicts Parkinson's Disease Risk in Patients With Essential Tremor and Undetermined Tremor: Dual-Cohort Longitudinal Evidence With 8-Year Follow-Up and Bayesian Validation.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic value of multi-regional multi-parameter transcranial sonography in differentiating Parkinson's disease from essential tremor.Frontiers in neurology · 2026Article
- Substantia Nigra Hyperechogenicity Predicts Parkinson's Disease Risk in Patients With Essential Tremor and Undetermined Tremor: Dual-Cohort Longitudinal Evidence With 8-Year Follow-Up and Bayesian Validation.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
objectivesTranscranial sonography (TCS)-detected substantia nigra hyperechogenicity (SN+) is a potential biomarker for Parkinson's disease (PD). While SN+ may indicate PD risk in essential tremor (ET), longitudinal undetermined tremor (UT) data are lacking; insufficient cross-cohort validation hinders clinical translation. This study aimed to evaluate the predictive efficacy of SN+ for 8-year PD risk and its subtype-specific differences in ET/UT populations.
methods180 patients with tremors who underwent TCS were enrolled and categorized based on the tremor type (ET/UT) and SN echogenicity grade (SN+/SN-). 127 patients (59 with ET, 68 with UT) completed a mean follow-up period of 8.01 years (range: 7.41-8.67; median: 7.92), during which new-onset PD was documented.
resultsIn the ET cohort, 52.4% of SN+ individuals developed PD, compared to 7.9% in the SN- group. For UT, the PD incidence was 91.2% in SN+ individuals and 50.0% in SN- individuals. Multivariable-adjusted Firth logistic regression revealed significant associations between SN+ and PD in the ET and UT groups. Moreover, Bayesian logistic regression confirmed SN+ was significantly associated with PD risk in both groups. The posterior probability of an odds ratio exceeding 5 for SN+ was greater than 80% in both cohorts. Subgroup interaction analysis demonstrated no evidence of effect modification by tremor subtype, indicating consistent SN+ effects across cohorts.
conclusionsTCS-detected SN+ is a predictor of PD progression over 8 years in both ET and UT cohorts. The consistent risk association across tremor subtypes in SN+ subgroups supports its clinical potential as a cross-tremor subtype biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.